Document is current
Any future updates will be listed below
-
Authors
Matsumoto, Masanori
Shimono, Akihiko
Yokosawa, Jun
Hirose, Keiichiro
Wang, Edward
Maruyama, Shoichi
- License Information
-
More Information
Article History
Received: 9 May 2024
Accepted: 9 September 2024
First Online: 28 October 2024
Declarations
:
: The ALXN1210-aHUS-311 phase III study protocol was approved by the Institutional Review Board or Independent Ethics Committee at each participating center, and the study was conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines.
: Informed consent was obtained from the individual participants for the original study. The current study reports a post-hoc analysis and additional consent was not required.
: M. Matsumoto received research funding and honoraria for lectures and participation on an advisory board from Alexion Pharma GK. A. Shimono, J. Yokosawa, and K. Hirose are employees of Alexion Pharma GK and shareholders of AstraZeneca. E. Wang is an employee of Alexion, AstraZeneca Rare Disease, and a shareholder of AstraZeneca. S. Maruyama received research funding and honoraria for lectures and participation on an advisory board from Alexion Pharma GK.
